Low molecular weight heparins in nephrologists practice


如何引用文章

全文:

详细

Indications and pathogenetic basis of low molecular weight heparins in nephrological practice are discussed. Approaches to prevention and treatment of thrombosis in nephrotic syndrome and renal failure are reviewed

作者简介

- -

参考

  1. Кутырина И. М., Никишова Т. А., Лифшиц Н. Л., Александровская Т.Н. К механизму диуретического эффекта гепарина при хроническом гломерулонефрите Терапевт. архив. 1982; 7: 42 - 46.
  2. Кутырина И. М., Никишова Т. А., Тареева И. Е. Гипотензивное и диуретическое действие гепарина у больных хроническим гломерулонефритом Терапевт.архив. , 1985; 6: 78 - 81.
  3. Mandal A. K., Lyden T. W., Saklaen M. G., Heparin lowers blood pressure. Kidney Int. 1995;. 47: 1017 - 1022.
  4. Gambaro G., Baggio B. Glycosoaminoglicans: a new paradigm in the prevention of proteinuria and progression of glomerular disease. Nephrol. Dial. Transplant., 1996;11:762 - 764.
  5. Gambaro G.; Morita Y., Makino H., Ota K., et. al. Effect of heparin and low- molecular - weight- heparin on proliferative glomerulonephritis Nippon-Jinzo-Gakkai-Shi., 1994; 36:p.823 - 838.
  6. Striker G. E., Lupia E., Eliot S. et al. Glomerulosclerosis, arteriosclerosis and vascular graft stenosis: Treatment with oral heparinoids. Kidney Int. 1997; 52:S120 - S123.
  7. Abilgaard U, Lindahl AL, Sandset PM. Heparin requires both antithrombin and extrinsic pathway inhibitor for its anticoagulant effect in human blood. Haemostasis.1991;21:254-257.
  8. Hoppensteadt DA, Walenga JM, Fasanella A et al. TFPI antigen levels in normal human volunteers after intravenous and subcutaneous administration of unfractionated heparin and a low molecular weight heparin. Thromb Res 1995; 77:175-181.
  9. Sandset PM, Bends B, Hancen JB. Physiological function of tissue factor pathway inhibitor and interaction with heparins. Haemostasis 2000; 30(suppl 2):48-56.
  10. Vila V, Martinez-Sales V, Reganon E et al Effects of unfractionated and low molecular weight heparins on plasma levels of hemostatic factors in patients with acute coronary syndromes. Haematologica 2001; 86:729-734.
  11. Yamamoto N, Ogawa H, Oshima S et al. The effect of heparin on tissue factor and tissue factor pathway inhibitor in patients with acute myocardial infarction. Int J Cardiol 2000; 75:267-274.
  12. Cadroy Y, Gaspin D, Duppuy D et al Heparin reverses the procoagulant properties of stimulated endothelial cells Thromb Haemost 1996; 75: 190-195
  13. Pepe G, Guisti B, Attanasio M et al Tissue factor and plasminogen activator inhibitor type 2 expression in human stimulated monocytes is inhibited by heparin Semin Thromb Hemost 1997; 23:135-141.
  14. Weithz JL Low molecular weight heparins. N Engl J Med 1997;337:688-699.
  15. Cardoy Y, Pourrat J, Balagre MF et al. Delayed elimination of enoxaparin in patients with chronic renal insufficiency. Thromb Res 1991; 63:385-390.
  16. Orth SR, Ritz E. The nephrotic syndrome N Eng Jorn Med 1998;338:1202-1211.
  17. Llach F. Hypercoagulability, renal vein thrombosis and other thrombotic complications of nephrotic syndrome. Kidney Int. 1985; 28:429-436.
  18. Crew RJ, Radhakrishnan S, Appel G. Complications of nephrotic syndrome and their treatment. Clin Nephrol. 2004; 62: 245-251.
  19. Donckerwolcke RA, Cameron JS The nephrotic syndrome: management, complications and pathophysiology. In Davison A.M., Cameron J. S., Grunfeld J.P., Ponticelli C., Ritz E., Winearls C., Ypersele C. (Ed.) Oxford Textbook of Clinical Nephrology, Third Edition. Oxford University Press, 2005. 415-436.
  20. Rabelink T.J., Zwaginga J.J., Koomans H.F. et al. Thrombosis and hemostasis in renal disease. Kidney Int 1994; 46: 287-296.
  21. Robert A, Olmer M, Sampol J et al..Clinical correlation between hypercoagulability and thrombo-embolic phenomena. Kidney Int 1994; 45:578-585.
  22. Mahmoodi BK, Ten Kate MK, Waanders F, et al. High absolute risks and predictors of venous and arterial thromboembolic events in patients with nephrotic syndrome. Results from a large retrospective cohort srudy. Circulation 2008;117:224-230.
  23. Bertina RM Genetic approach to thrombophilia. Thromb Haemost 2001;86: 92-99.
  24. Баранникова Е.И., Козловская Н.Л., Понкина О.Н., Семенченко Н.А. Генетическая гипергомоцистеинемия как причина артериальных и венозных тромбозов у больного хроническим гломерулонефритом. Нефрология и диализ 2008: т.10, № 3-4; с.254-258.
  25. Bellomo R, Atkins RC. Membranous nephropathy and thromboembolism: is prophylactic anticoagulation warranted? Nephron 1993;63:249-254.
  26. Clagett G, Anderson F, Geerts WH, et al. Prevention of venous thromboembolism Chest 1998; 114 (Suppl): 531S-560S.
  27. Attia J, Ray J, Cook DJ et al. Deep venous thrombosis and its prevention in critically ill adults. Arch Intern Med.2001;161(10):1268-1279.
  28. Cook DJ, Crowter M, Meade M et al. Deep venous thrombosis in medical-surgical critically ill patients: prevalence, incidence and risk factors. Crit Care Med.2005;33(7):1268-1279.
  29. Geerts WH, Pineo GF, Heit AJ et al. Prevention of venous thromboembolism: the seventh ACCP Conference on antithrombotic and thrombolytic therapy Chest 2004; 126 (3 Suppl): 338S-400S.
  30. Samama M, Cohen A, Darmon JY et al. Сравнение эффективности эноксапарина и плацебо в профилактике тромбозов и эмболий у пациентов с острыми терапевтическими заболеваниями. Клин Фарм Терапия 2001; 10:90-95.
  31. Leizorovicz A, Cohen AT, Turpie AG et al. Randomized, placebo-controlled trial of dalteparin for prevention of venous thromboembolism in acutely ill medical patients. Circulation 2004;110:874-879.
  32. Monreal M, Falga C, Valle R et al. Venous thromboembolism in patients with renal insufficiency: finding from the RIETE Registry. Am J Med. 2006;119:1073-1079.
  33. Wattanakit K, Cushman M, Stehman-Breen C, et al. Chronic kidney disease increased risk for venous thromboembolism. J Am Soc Nephrol 2008; 19:135-140.
  34. Tveit DP, Hypolite IO, Hshieh P et al. Chronic dialysis patients have high risk for pulmonary embolism. Am J Kidney Dis 2002; 39:1011-1017.
  35. Daneschvar HL, Seddighzadeh A, Piazza G, Goldhaber SZ. Deep vein thrombosis in patients with chronic kidney disease Thromb Haemost 2008; 99:1035-1039.
  36. D'Elia JA, Weinrauch LA, Gleason RE, et al. Risk factors for thromboembolic events in renal failure. Int J Cardiol.2005; 101:19-25.
  37. Caglar K, Peng Y, Pupim LB, et al. Inflammatory signals associated with hemodialysis. Kidney Int.2002; 62:1408-1416.
  38. Ando M, Iwata A, Ozeki Y, et al. Circulated platelet-derived microparticles with procoagulant activity may be a potential cause of thrombosis in uremic patients. Kidney Int. 2002; 62:1757-1763.
  39. Reich LM, Folsom AR, Key NS, et al. Prospective study of subclinical atherosclerosis as a risk for venous thromboembolism. J Thromb Haemost. 2006; 4:1909-1913.
  40. Singh AK, Szczech L, Tang KL, et al. Correction of anemia with epoetin alfa in chronic kidney disease. N Engl J Med. 2006; 355:2085-2098.
  41. Lim W, Dentali F, Eikelboom JW, Crowter MA. Meta-analysis: low-molecular-weight heparin and bleeding in patients with severe renal insufficiency. Ann Intern Med 2006; 144:673-684.
  42. Falga C, Capdevila JA, Soler S et al. Clinical outcome of patients with venous thromboembolism and renal insufficiency. Findings from the RIETE registry. Thromb Haemost 2007; 98(4):771-776.
  43. Santopino JJ, Fox KA, Goldberg RJ et al. Creatinine clearance and adverse hospital outcomes in patients with acute coronary syndromes: finding from the global registry of acute coronary events (GRACE). Heart 2003; 89(9):1003-1008.
  44. Thorevska N, Amoateng-Adjepong Y, Sabahi R, et al. Anticoagulation in hospitalized patients with renal insufficiency: a comparison of bleeding rates with unfractionated heparin vs enoxaparin. Chest 2004; 125:856-863.
  45. Antman EM, McCabe CH, Gurfinkel EP, et al. Enoxaparin prevents death and cardiac ischemic events in unstable angina/non-Q-wave myocardial infarction. Results of the thrombolysis in myocardial infarction (TIMI) IIB trial. Circulation 1999; 100:1593-160.
  46. Collet JP, Montalescot G, Agnelli G, et al. Non-ST-segment elevation acute coronary syndrome in patients with renal dysfunction: benefit of low-molecular-weight heparin alone or with glycoprotein IIb/IIIa inhibitors on outcomes. The Global Registry of Acute Coronary Events. Eur Heart J 2005; 26:2285-2293.
  47. Collet JP, Montalescot G, Fine E, et al. Enoxaparin in unstable angina patients who would have been excluded from randomized pivotal trials. J Am Coll Cardiol. 2003; 41:8-14.
  48. Schmid P, Fisher AG, Wuillemin WA. Low-molecular-weight heparin in patients with renal insufficiency. Swiss Med WKLY 2009; 139(31-32):438-452.
  49. Collet JP, Montalescot G, Choussat R, et al. Enoxaparin in unstable angina patients with renal failure Int J Cardiol. 2001; 80:81-82.
  50. Frydman A. Low-molecular-weight heparins: an overview of their pharmacodynamics, pharmacokinetics and metabolism in humans. Hemostasis 1996; 26 (Suppl 2):24-38.
  51. Samama MM, Gerotziafas GT. Comparative pharmacokinetics of LMWHs.Semin Thromb Hemost 2000; 26 (Suppl 1):31-38.
  52. Schmid P, Fischer AG, Wuillemin WA. Low-molecular-weight heparin in patients with renal insufficiency Swiss Med WKLY 2009; 139(31-32):438-452.
  53. Tincani E, Mannucci C, Casolari B, et al. Safety of dalteparin for the prophylaxis of venous thromboembolism in elderly medical patients with renal insufficiency: a pilot study. Haematologica 2006; 91:976-979.
  54. Stöbe J, Siegemund A, Achenbach H et al. Evaluation of the pharmacokinetics of dalteparin in patients with renal insufficiency. Int J Clin Pharmacol Ther. 2006; 44:455-465.
  55. Cook D, Douketis J, Meade M et al. Venous thromboembolism and bleeding in critically ill patients with severe renal insufficiency receiving dalteparin thromboprophylaxis: prevalence, incidence and risk factors. Crit Care 2008; 12:R32.
  56. Douketis J, CooK D, Meade M et al .Prophylaxis against deep vein thrombosis in critically ill patients with severe renal insufficiency with the low-molecular-weight heparin dalteparin: an assessment of safety and pharmacodynamics: the DIRECT study. Arch Intern Med.2008; 168(16):1805-1812.
  57. Schmid P, Brodmann D, Fischer AG, Wuillemin WA. Study of bioaccumulation of dalteparin at a prophylactic dose in patients with various degrees of impaired renal function. J Thromb Haemost 2009; 7:552-558.
  58. Rabbat CG, Cook D, Crowter MA, et al. Dalteparin thromboprophylaxis for critically ill medical-surgical patients with renal insufficiency J Crit Care 2005;20:357-363.
  59. Geerts WH, Bergqvist D, Pineo GF, et al. Prevention of venous thromboembolism: American college of chest physicians evidence-based clinical practice guidelines (8th edition.) Chest 2008; 133: 381S-453S.
  60. Schulman S, Beyth RJ, Kearon C, Levine MN. Hemorrhagic complications of anticoagulant and thrombolytic treatment: American college of chest physicians evidence-based clinical practice guidelines (8th edition). Chest 2008; 133:257S-298S.
  61. Samama MM, Cohen AT, Darmon JY, et al. A comparison of enoxaparin with placebo for the prevention of venous thromboembolism in acutely ill medical patients. Prophylaxis in medical patients with enoxaparin study group. N Engl J Med.1999; 341:793-800.
  62. Schmid P, Fisher AG, Wuillemin WA. Prevalence of impaired renal function in medical inpatients. Swiss Med Wkly.2007; 137:514-516.
  63. Cook LM, Kahn SR, Goodwin J, Kovacs MJ. Frequency of renal impairment, advanced age, obesity and cancer in venous thromboembolism patients in clinical ptactice. J Thromb Haemost. 2007; 5(5):937-941.
  64. Alexander KP, Chen AY, Roe MT , et al. Excess dosing of antiplatelet and antithrombin agents in the treatment of non-ST-segment elevation acute coronary syndromes. JAMA 2005; 294:3108-3116.
  65. La Pointe NM, Chen AY, Alexander KP, et al. Enoxaparin dosing and associated risk of in-hospital bleeding and death in patients with non ST-segment elevation acute coronary syndromes. Arch Intern Med.2007; 167(14):1539-1544.
  66. Hirsh J, Bauer KA, Donati MB, et al. Parenteral anticoagulants: American college of chest physicians evidence-based clinical practice guidelines (8th edition). Chest 2008; 133:141S-159S.
  67. Fareed J, Leong WL, Hoppensteadt DA, et al. Generic low-molecular-weight heparins: some practical considerations. Semin Thromb Hemost. 2004; 30:703-713.

补充文件

附件文件
动作
1. JATS XML
下载
##common.cookie##